TEVA240823P17500
- 0.01
- -0.01-50.00%
Teva Pharmaceutical Industries Newsroom
BofA Securities Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Express News | Teva : BofA Global Research Raises Price Objective to $22 From $21
Generic Weight-Loss Drugs Won't Come for Years -- Barrons.com
$1000 Invested In This Stock 5 Years Ago Would Be Worth $2,400 Today
Medincell: Participation Terms in the Combined General Meeting
Glenview Capital's Q2 Moves Include Selling Broadcom After Just One Quarter, Exiting Meta
Teva Pharmaceutical Industries Options Spot-On: On August 14th, 82,334 Contracts Were Traded, With 730.61K Open Interest
Teva Pharmaceutical Hits a New 52-week High
$100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
Teva Pharmaceutical Industries Insider Sold Shares Worth $782,972, According to a Recent SEC Filing
Harris Leads Trump in Polls. Which Stocks Could Benefit from Her Policies?
Express News | Teva : HSBC Raises Target Price to $23 From $20
Teva Pharmaceutical Industries Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $22
Argus Research Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Evercore Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating
Teva Pharmaceutical Industries Limited (NYSE:TEVA) Second-Quarter Results Just Came Out: Here's What Analysts Are Forecasting For This Year
Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Raises Target Price to $22
Express News | Barclays Maintains Overweight on Teva Pharmaceutical Indus, Raises Price Target to $22
Teva Pharmaceutical Indus Analyst Ratings